--- title: "12 Health Care Stocks Moving In Tuesday's After-Market Session" type: "News" locale: "en" url: "https://longbridge.com/en/news/295584717.md" description: "Several healthcare stocks experienced significant volatility in Tuesday's after-market session, largely driven by Q2 earnings reports. Gainers included Dermata Therapeutics (up 44.4%), CytoSorbents (up 11.11%), and Mereo BioPharma (up 8.01%). Conversely, major losers featured Edap TMS (down 21.8%), Absci (down 16.16%), and WORK Medical Tech (down 10.32%). The session highlighted the impact of recent financial disclosures on small-cap biotech and medical device companies." datetime: "2026-08-11T21:06:27.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295584717.md) - [en](https://longbridge.com/en/news/295584717.md) - [zh-HK](https://longbridge.com/zh-HK/news/295584717.md) --- # 12 Health Care Stocks Moving In Tuesday's After-Market Session ### Gainers - **Dermata Therapeutics** (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday's after-market session. The company's market cap stands at $4.5 million. As per the news, the Q2 earnings report came out today. - **CytoSorbents** (NASDAQ:CTSO) stock moved upwards by 11.11% to $0.4. The company's market cap stands at $22.7 million. As per the news, the Q2 earnings report came out 3 days ago. - **Mereo BioPharma Group** (NASDAQ:MREO) shares rose 8.01% to $0.33. The market value of their outstanding shares is at $43.4 million. As per the news, the Q2 earnings report came out today. - **LENZ Therapeutics** (NASDAQ:LENZ) shares moved upwards by 7.86% to $5.62. The company's market cap stands at $168.0 million. The company's, Q2 earnings came out today. - **60 Degrees** (NASDAQ:SXTP) stock moved upwards by 7.07% to $1.21. The market value of their outstanding shares is at $3.0 million. - **Accuray** (NASDAQ:ARAY) stock rose 7.0% to $0.31. The market value of their outstanding shares is at $34.9 million. ### Losers - **Edap TMS** (NASDAQ:FOCL) stock decreased by 21.8% to $4.7 during Tuesday's after-market session. The market value of their outstanding shares is at $227.8 million. - **Absci** (NASDAQ:ABSI) shares decreased by 16.16% to $7.89. The market value of their outstanding shares is at $1.5 billion. As per the press release, Q2 earnings came out today. - **WORK Medical Tech Gr** (NASDAQ:WOK) shares declined by 10.32% to $2.0. The company's market cap stands at $5.0 million. - **Concord Medical Services** (NYSE:CCM) shares decreased by 9.08% to $4.71. The company's market cap stands at $18.8 million. - **Apollomics** (NASDAQ:APLM) stock fell 7.76% to $17.0. The market value of their outstanding shares is at $39.1 million. - **Cardiff Oncology** (NASDAQ:CRDF) stock fell 7.61% to $0.97. The market value of their outstanding shares is at $80.1 million. As per the news, the Q2 earnings report came out today. **See Also:** www.benzinga.com/money/best-healthcare-stocks/ This article was generated by Benzinga's automated content engine and reviewed by an editor. ### Related Stocks - [DRMA.US](https://longbridge.com/en/quote/DRMA.US.md) - [CTSO.US](https://longbridge.com/en/quote/CTSO.US.md) - [EDAP.US](https://longbridge.com/en/quote/EDAP.US.md) - [DRMAW.US](https://longbridge.com/en/quote/DRMAW.US.md) - [ABSI.US](https://longbridge.com/en/quote/ABSI.US.md) - [WOK.US](https://longbridge.com/en/quote/WOK.US.md) - [MREO.US](https://longbridge.com/en/quote/MREO.US.md) - [LENZ.US](https://longbridge.com/en/quote/LENZ.US.md) - [SXTP.US](https://longbridge.com/en/quote/SXTP.US.md) - [ARAY.US](https://longbridge.com/en/quote/ARAY.US.md) - [FOCL.US](https://longbridge.com/en/quote/FOCL.US.md) - [CCM.US](https://longbridge.com/en/quote/CCM.US.md) - [APLM.US](https://longbridge.com/en/quote/APLM.US.md) - [CRDF.US](https://longbridge.com/en/quote/CRDF.US.md) - [SXTPW.US](https://longbridge.com/en/quote/SXTPW.US.md) - [APLMW.US](https://longbridge.com/en/quote/APLMW.US.md) ## Related News & Research - [CytoSorbents posts investor presentation outlining Q2 revenue, cash burn progress toward breakeven](https://longbridge.com/en/news/295602568.md) - [Mereo BioPharma signs option-and-license deal with Sentynl for US rights to alvelestat in AATD lung disease](https://longbridge.com/en/news/295533220.md) - [Absci (ABSI) Could Be 32% Undervalued Following ABS 201 Data And Earnings](https://longbridge.com/en/news/295686913.md) - [AbSci: Buy Rating Reaffirmed as ABS-201 Hair-Loss Program Advances; $11 Price Target Maintained](https://longbridge.com/en/news/295652271.md) - [Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights | MREO Stock News](https://longbridge.com/en/news/295535880.md)